UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

For the month of July 2018

Commission File Number: 001-37847

MOTIF BIO PLC

(Translation of registrant's name into English)

125 Park Avenue
25th Floor
New York , New York 10017
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

MOTIF BIO PLC
FORM 6-K

RESIGNATION OF ROBERT BERTOLDI FROM BOARD OF DIRECTORS

On July 3, 2018, Motif Bio plc (the "Company") issued a press release, a copy of which is attached as Exhibit 99.1 to this report on Form 6-K, to announce that Robert Bertoldi has informed the Company of his decision to resign from the Board of Directors, effective July 16, 2018.

The information contained in this report on Form 6-K, excluding the press release attached as Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File Nos. 333-222614 and 333-222042), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibits

Exhibit 99.1	Press release issued by Motif Bio plc, dated July 3, 2018, entitled "Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MOTIF BIO PLC

Date: July 3, 2018

By: /s/ Graham Lumsden
Name: Graham Lumsden
Title: Chief Executive Officer

EXHIBIT 99.1

Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors

NEW YORK, July 03, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has informed the Company of his decision to resign from the Board of Directors, effective July 16, 2018.

Graham Lumsden, Chief Executive Officer of Motif Bio, said: *"On behalf of the Board, we are grateful to Bob for his dedication and service to the company since its inception. We have appreciated his insight and wish him future success."*

For further information please contact:

Motif Bio plc Graham Lumsden (Chief Executive Officer)	info@motifbio.com
Peel Hunt LLP (NOMAD & BROKER) Dr Christopher Golden Oliver Jackson	+ 44 (0)20 7418 8900
Northland Capital Partners Limited (BROKER) David Hignell/John Howes/Rob Rees	+44 (0)203 861 6625
Walbrook PR Ltd. (UK FINANCIAL PR & IR) Paul McManus/Helen Cresswell/Lianne Cawthorne	+44 (0) 20 7933 8780
MC Services AG (EUROPEAN IR) Raimund Gabriel	+49 (0)89 210 2280 raimund.gabriel@mc-services.eu
Solebury Trout (U.S. IR) Meggie Purcell	+ 1 (646) 378-2936 mpurcell@troutgroup.com
Russo Partners (U.S. PR) David Schull Travis Kruse, Ph.D.	+1 (858) 717-2310 or +1 (212) 845 4272 david.schull@russopartnersllc.com travis.kruse@russopartnersllc.com

Note to Editors:

About Motif Bio

Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for hospitalised patients and designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria, including MRSA. The Company's lead product candidate is iclaprim. Following positive results from two Phase 3 trials (REVIVE-1 and REVIVE-2), an NDA has been submitted to the U.S. FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSI). More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment. The Company believes, based on the data from the Phase 3 REVIVE studies, that iclaprim may be suitable for first-line empiric therapy in ABSSSI patients, including those with renal impairment, with or without diabetes.

The Company also plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of *Staphylococcus aureus* lung infections in patients with cystic fibrosis and is in preclinical development for this indication.

Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status. Upon acceptance by the FDA of an NDA, iclaprim will receive Priority Review status and, if approved as a New Chemical Entity, will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated.

Forward-Looking Statements

This press release contains forward-looking statements. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Motif Bio's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Motif Bio believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for Motif Bio's product candidates, (ii) the timing, scope or likelihood of regulatory filings and approvals for Motif Bio's product candidates, (iii) Motif Bio's ability to successfully commercialise its product candidates, (iv) Motif Bio's ability to effectively market any product candidates that receive regulatory approval, (v) Motif Bio's commercialisation, marketing and manufacturing capabilities and strategy, (vi) Motif Bio's expectation regarding the safety and efficacy of its product candidates, (vii)

the potential clinical utility and benefits of Motif Bio's product candidates, (viii) Motif Bio's ability to advance its product candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) Motif Bio's estimates regarding the potential market opportunity for its product candidates, and (x) the factors discussed in the section entitled "Risk Factors" in Motif Bio's Annual Report on Form 20-F filed with the SEC on April 10, 2018, which is available on the SEC's web site, www.sec.gov. Motif Bio undertakes no obligation to update or revise any forward-looking statements.